Lead researcher
Dr Nirmala Chandralega-Kampan
Main finding
Interleukin-6 (IL-6) in ascites fluid can increase the proportion of TNFR2+ T-regulatory cells (Tregs), to inhibit the activity of anti-tumour T-effector cells (Teffs) and promote immune suppression. Blockade of IL-6 signalling decreased immune suppression, decreased the expression of several checkpoint inhibitor molecules, and increased Teff activity.
Centre
Centre for Cancer Research
Research group
Ovarian Cancer Biomarkers
Journal and article title
Most surprising
Immune-suppressive TNFR2+ Tregs can arise de novo through the influence of IL6, rather than migrating into the tumour environment as previously hypothesized. These TNFR2+ Tregs have potent immunosuppressive activity, and inhibit TNFR2+ T effector cells to enhance immune suppression in ovarian cancers.
Future implications
The use of therapies to antagonize IL-6 signalling can stimulate anti-tumour immunity through a reduction in Treg abundance, whilst simultaneously increasing T effector cell function. This could lead to novel adjunct therapies for patients.
Disease/health impact
ovarian cancer